Episode Details
Back to Episodes2025 San Antonio Breast Cancer Symposium: Evolving First-Line Approaches in Metastatic HER2+ Breast Cancer
Episode 622
Published 4 months, 3 weeks ago
Description
Drs. Isaacs and Traina discuss DESTINY-Breast09, where first‑line T‑DXd + pertuzumab clearly outperforms the CLEOPATRA regimen in progression-free survival for metastatic HER2+ breast cancer. They focus on the dilemma of when to use T‑DXd: earlier, for maximal efficacy, or later, to protect quality of life and manage ILD and cardiac risks.